Zahra Almosawi
Psychiatric/Mental Health · Woodbridge, VANPI 1497345813
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,296, 5.1 times the $453 reported in 2021. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$772
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$679
- Otsuka America Pharmaceutical, Inc.$603
- Lundbeck LLC$580
- Vanda Pharmaceuticals Inc.$488
- Alkermes, Inc.$369
- plus $2K from 17 others
What the payments were for
- Food & beverage$5,597100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $772 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $679 |
| Otsuka America Pharmaceutical, Inc. | 33 | $603 |
| Lundbeck LLC | 28 | $580 |
| Vanda Pharmaceuticals Inc. | 20 | $488 |
| Alkermes, Inc. | 19 | $369 |
| Neurocrine Biosciences, Inc. | 15 | $350 |
| Axsome Therapeutics, Inc. | 11 | $324 |
| Supernus Pharmaceuticals, Inc. | 14 | $272 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $270 |
| Johnson & Johnson | 8 | $214 |
| Teva Pharmaceuticals USA, Inc. | 12 | $153 |
| Corium, LLC | 5 | $109 |
| E.r. Squibb & Sons, L.L.C. | 3 | $74 |
| Sunovion Pharmaceuticals Inc. | 4 | $73 |
| Avanir Pharmaceuticals, Inc. | 4 | $62 |
| Indivior Inc. | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 1 | $48 |
| Collegium Pharmaceutical, Inc. | 2 | $40 |
| TMS Neurohealth Centers Inc. | 1 | $30 |
| Tris Pharma Inc | 1 | $21 |
| Neos Therapeutics, LP | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
How this compares
$5,621 in reported general payments places this provider in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 11 | $4,635 |
| Olanzapine | 78 | $3,532 |
| Methylphenidate Er (La)Methylphenidate Hcl | 17 | $3,333 |
| Lisdexamfetamine Dimesylate | 14 | $3,093 |
| Aripiprazole | 57 | $3,084 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 23 | $1,663 |
| Vilazodone Hcl | 28 | $1,461 |
| Quetiapine Fumarate | 60 | $1,271 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 51 | $1,212 |
| Duloxetine Hcl | 36 | $909 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $845 |
| Pregabalin | 16 | $720 |
| Haloperidol | 19 | $717 |
| Bupropion XlBupropion Hcl | 22 | $666 |
| Buspirone Hcl | 41 | $584 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Woodbridge
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Juliana FroschAmherst$36K
- Derick ReedyNickelsville$23K
- Pamela RuppelRoanoke$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.